The Cancer Survivors Network (CSN) is a peer support community for cancer patients, survivors, caregivers, families, and friends! CSN is a safe place to connect with others who share your interests and experiences.

Thank you for being a part of the Cancer Survivor Network community. Survivors and caregivers like you have played a unique role in fostering an online environment that encourages connection among those needing support, community, and education. On May 28, the Network will be discontinued. More details are available here . If you have any questions, contact CSNSupportTeam@cancer.org. Thanks again for the support you’ve provided each other over the years. We remain committed to supporting you in other ways throughout your cancer journey.

New Clinical trial to see of Cabo will trump Sutent. This is great.

sblairc
sblairc CSN Member Posts: 585 Member
in Kidney Cancer #1

Cabozanitinub is going to start studies to see if it will become a FIRST IN LINE drug for kidney cancer. 

This means that there could be a drug to come out ahead of the one already prescribed first, Sutent. 

I think the article says a Phase 3 trial is going to start of the drug.

http://www.fool.com/investing/2016/05/27/this-new-data-could-push-exelixis-cabometyx-over-1.aspx

 

This means we are getting another drug that will likely prolong survival. 

Like Care

Comments

  • Yeric
    Yeric CSN Member Posts: 65
    #2
    another drug

    I don't remember what drug I was getting that I was told  " There is'nt anything after this."  I do remember that it wasn't that long ago.  And here we are with new stuff to try faster than I can burn through what I am taking.  So, how many shares of drug company do I need to break even with treatment from said company??  Thanks for the link sblairc!!

    Bobby

    Like Care

Discussion Boards